Li Ziyi, Wu Liangzhi, Zhang Junguo, Huang Xin, Thabane Lehana, Li Guowei
Centre for Clinical Epidemiology and Methodology, Guangdong Second Provincial General Hospital, Guangzhou, China.
Department of Gynecology, Guangdong Second Provincial General Hospital, Guangzhou, China.
Front Nutr. 2021 Apr 1;8:655727. doi: 10.3389/fnut.2021.655727. eCollection 2021.
Laboratory findings indicated that vitamin D might have a potent protective effect on breast cancer, but epidemiology studies reported conflicting results. The aim of the study was to conduct a systematic review and meta-analysis to clarify the efficacy of vitamin D supplementation on risk of breast cancer. MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and abstracts of three major conferences were searched (up to December 8, 2020). Parallel randomized controlled trials (RCTs) examining the efficacy of vitamin D supplementation on risk of breast cancer or change of mammography compared with placebo in females were included. Data were meta-analyzed using a random-effects model. Bayesian meta-analysis was conducted to synthesize the results using data from observational studies as priors. Seven RCTs were identified for effect of vitamin D on risk of breast cancer, with 19,137 females included for meta-analysis. No statistically significant effect of vitamin D on risk of breast cancer was found in classical random-effects meta-analysis (risk ratio = 1.04, 95% confidence interval: 0.84-1.28, = 0.71). When Bayesian meta-analyses were conducted, results remained non-significant. There was no statistically significant effect of vitamin D on mammography density observed: mean difference = 0.46, 95% confidence interval: -2.06 to 2.98, = 0.72. There is insufficient evidence to support the efficacy of vitamin D supplementation in breast cancer risk and change of mammography density. The protective effect of vitamin D on risk of breast cancer from previous observational studies may be overestimated. PROSPERO, identifier CRD42019138718.
实验室研究结果表明,维生素D可能对乳腺癌具有强大的保护作用,但流行病学研究报告的结果却相互矛盾。本研究的目的是进行系统评价和荟萃分析,以阐明补充维生素D对乳腺癌风险的疗效。检索了MEDLINE、EMBASE、Cochrane对照试验中央注册库、ClinicalTrials.gov以及三大会议的摘要(截至2020年12月8日)。纳入了平行随机对照试验(RCT),这些试验研究了与安慰剂相比,补充维生素D对女性乳腺癌风险或乳房X线摄影变化的疗效。使用随机效应模型对数据进行荟萃分析。进行贝叶斯荟萃分析,以前瞻性研究的数据作为先验来综合结果。共确定了7项关于维生素D对乳腺癌风险影响的RCT,纳入荟萃分析的女性有19137名。在经典随机效应荟萃分析中,未发现维生素D对乳腺癌风险有统计学意义的影响(风险比=1.04,95%置信区间:0.84-1.28,P=0.71)。进行贝叶斯荟萃分析时,结果仍然不显著。观察到维生素D对乳房X线摄影密度没有统计学意义的影响:平均差异=0.46,95%置信区间:-2.06至2.98,P=0.72。没有足够的证据支持补充维生素D对乳腺癌风险和乳房X线摄影密度变化的疗效。先前观察性研究中维生素D对乳腺癌风险的保护作用可能被高估了。国际前瞻性系统评价注册库,标识符CRD42019138718。